Clinical Uses of 1-Alpha-Hydroxy-Ergocalciferol.

Clinical Uses of 1-Alpha-Hydroxy-Ergocalciferol. Curr Vasc Pharmacol. 2013 May 16; Authors: Park J, Rhee C, Lau WL, Kalantar-Zadeh K Abstract Compared to such native vitamin D agents as cholecalciferol(D3), egocalciferol(D2), and calcifediol (25-hydroxy vitamin D3), which need 1-alpha hydroxylase to be activated, 1-alpha-ergocalciferol, also known as doxercalciferol, is a synthetically manufactured vitamin D analogue used for treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). Doxercalciferol exhibits more structural similarities to plant-based vitamin D2, ergocalciferol, than with animal-based vitamin D3, cholecalciferol. Because doxercalciferol does not have a 25-hydroxy group, it requires 25-hydroxylation by the liver to be activated, a process independent of kidneys. Doxercalciferol shares these features with its D3 equivalent, 1-alpha-hydroxy-cholecalciferol (alphacalcidol), both of which are activated hepatically and independent of renal or extra-renal 1-alpha hydroxylase. In experimental and clinical studies of CKD and SHPT, doxercalciferol effectively reduces parathyroid hormone levels and restores abnormal bone pathology. The efficacy of doxercalciferol is similar to other vitamin D analogues including calcitriol, alphacalcidol, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and maxacalcitol (1,25-dihydroxy-22-oxa-vitamin D3). The frequency and magnitude of hypercalcemia or hyperphosphatemia observed wit...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research